Trending Market News

Procter & Gamble is acquiring supplements brand Thorne in a move to expand its health and wellness division. CEO Shailesh Jejurikar announced the deal on CNBC, describing Thorne as a well-run operation. P&G already owns health brands including Vick's and Oral-B.

• The acquisition was announced by P&G CEO Shailesh Jejurikar on CNBC's 'Squawk on the Street' and is set to be formally announced on Tuesday
• The deal is part of P&G's strategy to grow its health and wellness business, which already includes brands like Vick's and Oral-B
• Jejurikar praised Thorne as 'a really well-run operation' that has been established for a long time

Moderna has launched its first human trial of an mRNA vaccine targeting the Bundibugyo Ebola strain, which has caused over 1,650 deaths and currently has no approved vaccine. The early-stage trial in Canada will enroll approximately 80 healthy adults to assess safety and immune response. The development is funded in part by a $50 million commitment from CEPI amid an ongoing outbreak in the Democratic Republic of Congo.

• The Bundibugyo strain is driving the world's largest Ebola outbreak on record in the Democratic Republic of Congo, with 3,748 confirmed cases and 1,657 deaths as of August 1, with cases increasing faster than previous outbreaks
• The experimental vaccine (mRNA-1469) uses the same mRNA technology as Moderna's COVID-19 vaccine and is being tested at three sites in Canada with Health Canada clearance
• If approved, Moderna plans to make at least 500,000 doses available to low- and middle-income countries at access pricing under its CEPI partnership agreement

New Jersey Attorney General Jennifer Davenport filed an antitrust lawsuit against Amazon.com on Tuesday, according to court records. The lawsuit adds to growing regulatory scrutiny of the e-commerce giant's business practices at the state level.

• The lawsuit was filed by New Jersey's AG on August 4, marking another state-level antitrust action against Amazon
• Specific allegations and details of the antitrust claims were not disclosed in the initial court filing
• The action comes amid broader regulatory efforts to address potential anticompetitive practices by major tech platforms

Jeff Bezos filed to sell approximately 15 million Amazon shares worth about $4 billion through a pre-arranged trading plan. The filing came after Amazon reached an all-time high following strong quarterly results driven by cloud computing and AI investments. Amazon shares fell more than 2% in early trading following the disclosure.

• The sale of 15 million shares was executed on Monday through Morgan Stanley under a Rule 10b5-1 trading plan adopted on November 14, 2025
• Amazon had just hit an all-time high after reporting robust quarterly results with stronger-than-expected cloud computing growth, boosting investor confidence in its AI investments
• Bezos has regularly sold Amazon stock in recent years through pre-arranged trading plans while remaining among the company's largest shareholders

Sysco exceeded Wall Street's fourth-quarter sales estimates, reporting a 4.7% increase to $22.12 billion compared to the expected $21.94 billion. The food distributor's performance was driven by improving orders from local and international customers despite ongoing macroeconomic uncertainty.

• Quarterly sales reached $22.12 billion, surpassing analyst estimates of $21.94 billion
• Sales grew 4.7% year-over-year, outpacing the expected 3.8% increase
• Performance reflects resilient demand from both domestic and international customers amid uncertain economic conditions

Fidelity National Information Services (FIS) cut its 2026 annual revenue and profit forecasts on August 4, causing shares to fall. The payments and banking processing firm cited economic uncertainty tied to the Iran war and U.S. trade policy, which has made institutions and retailers cautious about technology spending.

• FIS lowered its 2026 adjusted earnings forecast to $6.15-$6.24 per share from a prior range, and reduced revenue outlook to $13.63-$13.70 billion from $13.77-$13.85 billion
• Economic uncertainty from Iran war and U.S. trade policy is weighing on demand for certain banking and capital-markets products as clients delay technology investments
• Despite the outlook cut, CEO Stephanie Ferris noted banks continue investing in technology modernization and artificial intelligence, supporting ongoing demand for FIS products

Tesla's China-made electric vehicle sales increased 37.8% year-over-year in July 2026, reaching 93,579 units and marking nine consecutive months of growth. The gains come despite mixed European performance and mounting competition from Chinese rival BYD, which has outsold Tesla globally for three straight months. Speculation about a potential separation of Tesla's China business has raised investor concerns, given that 95% of the company's components are sourced locally in China.

• Tesla sold 93,579 Model 3 and Model Y vehicles from its Shanghai plant in July, up 37.8% from July 2025 and 5.0% from June 2026
• BYD has posted higher global sales than Tesla for three consecutive months through July, driven by strong exports particularly to Europe
• Approximately 95% of Tesla's components are sourced locally in China, making the company heavily exposed to the market despite CEO Elon Musk dismissing merger speculation as 'fake news'

Bending Spoons has agreed to acquire database and spreadsheet startup Airtable for $1.28 billion in cash, marking its first acquisition since going public last month. The deal represents a significant discount from Airtable's 2021 peak valuation of $11 billion and comes after the company raised over $1.4 billion in funding since its 2013 founding.

• Airtable's valuation has fallen dramatically from $11 billion in 2021 to approximately $2.25 billion (including cash equivalents), with the $1.28 billion acquisition price representing further decline
• The company generates approximately $480 million in annual recurring revenue as of June 2026, growing over 20% year-over-year, and serves more than 500,000 organizations including 80% of Fortune 100 companies
• Bending Spoons typically acquires companies at discounted valuations, then trims staff and streamlines products to run profitably; previous acquisitions include Evernote and other notable brands

Wayfair reported its strongest U.S. sales growth since 2020 during its fiscal second quarter, with revenue rising 8.7% to $3.1 billion. The online furniture retailer also achieved its highest free cash flow since 2020 at $301 million, beating Wall Street expectations on both revenue and earnings as it gains market share in a challenging home goods environment.

• U.S. sales grew 8.7% to $3.1 billion, the strongest growth since pandemic-era surge of 55% in 2020, while free cash flow reached $301 million
• Specialty retail brands grew nearly 20% and luxury brand Perigold surged over 35%, helping Wayfair attract higher-end consumers
• Company beat expectations with $3.52 billion total revenue vs. $3.47 billion expected and delivered 10.6 million orders, though average order value of $332 fell short of $337.57 estimate

German vaccine maker BioNTech significantly cut its 2026 full-year sales outlook due to weaker-than-expected COVID-19 vaccine demand. The company now expects revenue between €1.6 billion and €1.9 billion, down from its previous guidance of €2 billion to €2.3 billion. Second quarter revenue fell more than half to €105.6 million while net loss more than doubled to €820.8 million.

• Q2 revenue dropped 59% year-over-year to €105.6 million from €260.8 million, while net loss expanded to €820.8 million
• Sales outlook reduced by approximately 17-22% from March guidance, citing lower vaccine demand, existing stockpiles in Germany, and deferred milestone payments
• Company is cutting costs with adjusted R&D spending now projected at €2.0-2.3 billion for the year, down from previous estimate of up to €2.5 billion

Pfizer exceeded Wall Street's second-quarter profit expectations on August 4, driven by strong sales of its blood thinner Eliquis, and raised the lower end of its full-year revenue forecast. The company reported an adjusted profit of 77 cents per share and now expects annual sales of $60.5 billion to $62.5 billion, up from a previous range of $59.5 billion to $62.5 billion.

• Pfizer raised its full-year revenue guidance floor to $60.5 billion from $59.5 billion, while maintaining the upper end at $62.5 billion
• Strong demand for blood thinner Eliquis was the primary driver behind the profit beat
• The company is relying on newer medicines and its $10 billion Metsera acquisition to offset declining COVID revenue and establish presence in the obesity treatment market

Kimberly-Clark cut its annual sales and profit forecasts after false claims on Chinese social media alleging toxic formamide in its Huggies diapers significantly hurt second-quarter sales in China. Despite independent testing confirming product safety, the company expects continued near-term impact from the disruption in this major market, while also facing volume declines in North America due to sticky inflation pressuring lower-income consumers.

• China's market regulator announced an investigation into 'formamide issues in infant diapers' on June 22 without naming specific brands, and has provided no updates since
• Kimberly-Clark now expects 2026 organic sales growth to trail category averages by about 100 basis points, down from previous forecasts of growth in line with or above the 2.5% weighted category average
• North American volumes slipped 0.3% in Q2 as inflation and higher food and gas prices forced lower-income consumers to reduce spending

Merck beat Q2 estimates and raised its 2026 revenue outlook to $66.3-$67.3 billion due to strong sales growth from new drugs. However, the pharmaceutical giant slashed its profit guidance to $2.66-$2.76 per share from $5.04-$5.16 due to charges related to its acquisition of Terns Pharmaceuticals. The company is actively acquiring assets to offset looming generic competition for key drugs including Keytruda in 2028.

• Q2 revenue reached $16.61 billion (up 5% year-over-year), with Keytruda generating $8.37 billion including $463 million from a new injectable version designed to combat patent expiration
• Newer products showed strong momentum: Winrevair sales jumped 75% to $588 million and pneumococcal vaccine Capvaxive rose 42% to $184 million
• Merck faces imminent generic competition for diabetes drugs Januvia and Janumet later in 2026 and blockbuster Keytruda in 2028, driving its acquisition strategy

SpaceX is increasingly prioritizing its own Starlink satellite launches over commercial customers, with at least seven spacecraft companies told that Falcon 9 rockets are fully booked until 2028 or 2029. This shift reflects Starlink's dominance in SpaceX's business, accounting for 60% of the company's revenue in 2025, and threatens to squeeze out rival space companies that depend on SpaceX for orbital access.

• Starlink generated $11.4 billion in revenue for SpaceX in 2025, compared to $4.1 billion from its space and launch business, making internal satellite launches more profitable than serving external customers
• SpaceX's transition to the new Starship rocket and NASA obligations for moon landing missions starting in 2028 are creating a launch capacity bottleneck for commercial customers
• Falcon 9 launch prices have risen from $54 million in 2013 to roughly $74 million today, while competitors like Blue Origin's New Glenn and ULA's Vulcan remain grounded due to technical issues

The Trump administration is drafting a ban on U.S. imports of new Chinese data center components, specifically optical transceivers used in fiber-optic data transmission. The Federal Communications Commission is leading the effort, aiming to prevent Chinese firms from potentially stealing data, installing malware, or disrupting AI infrastructure before they become entrenched in the supply chain.

• The ban would primarily impact China's Zhongji Innolight, which holds a 27% market share and was added to the Pentagon's list of alleged Chinese military-backed companies in June
• U.S. cloud providers like Amazon Web Services may face higher costs as they transition to alternative suppliers such as Coherent and Lumentum
• The measure follows a pattern of FCC restrictions on Chinese tech firms and aims to avoid repeating the Huawei situation, where embedded Chinese equipment proved slow and expensive to remove

Volvo Cars reported a 4% decline in sales volumes for May-July, selling 164,663 vehicles compared to the same period last year. The downturn was primarily driven by weak performance in China, while the U.S. market showed recovery with double-digit growth for the third consecutive month. Europe, its largest market, remained stable with moderate growth.

• Electrified vehicle sales (fully electric and plug-in hybrids) surged 15% to represent 53% of total sales, with fully electric cars alone rising 21% to account for 27% of deliveries
• U.S. sales recovered with double-digit growth for a third straight month, while China's market downturn significantly impacted overall performance
• The company maintained pricing discipline in Europe and reported sustained increases in retail orders for fully electric vehicles

British medical products company Smith+Nephew reduced its full-year revenue growth forecast on Tuesday due to ongoing weakness in its orthopaedics division. The company's largest market, the United States, is the primary source of the underperformance affecting overall business results.

• The orthopaedics unit continues to underperform in the U.S. market, which is Smith+Nephew's largest market
• The company lowered its full-year revenue growth outlook as a result of the persistent weakness
• This marks a significant setback for the British medical device manufacturer's financial projections

BP reported second-quarter underlying replacement cost profit of $5.73 billion, more than doubling its profit from the same period a year ago. The results exceeded analyst expectations in a company-provided poll, reflecting strong performance in the energy sector.

• Q2 profit of $5.73 billion represents more than a 100% increase compared to the prior year period
• Results surpassed expectations according to a company-provided analyst poll
• The strong profit performance comes amid continued volatility in global energy markets

British warehouse landlord Segro has agreed to a takeover bid from U.S. logistics firm Prologis valued at up to £14.3 billion ($19.19 billion). The deal represents a major consolidation in the warehouse and logistics real estate sector.

• The acquisition is valued at up to $19.19 billion (£14.3 billion), making it a significant cross-border deal in the logistics property sector
• Prologis, a U.S.-based logistics real estate company, is acquiring Segro, a major British warehouse landlord
• The agreement marks continued consolidation in the warehouse sector, which has seen strong demand driven by e-commerce growth

Apple has requested a preliminary injunction against OpenAI and two former Apple employees now working for the AI company, seeking to block their access to alleged confidential information. The motion is part of Apple's lawsuit filed last month accusing the former employees of misappropriating trade secrets to benefit OpenAI's consumer hardware initiatives. OpenAI has denied the allegations, calling Apple's claims 'based on false information'.

• Apple is seeking expedited discovery and depositions of former senior system electrical engineer Chang Liu, former VP of product design Tang Yew Tan, and other OpenAI employees with Apple backgrounds
• The lawsuit represents escalating tension over future AI devices that could bypass traditional apps and operating systems, potentially threatening iPhone sales as OpenAI reportedly develops its own hardware
• OpenAI publicly refuted the allegations in a blog post, stating they 'do not have, nor want, any of their trade secrets'